Click to read
the new issue

April 2014

NICE 'no' for pulmonary fibrosis drug

UK News | November 29, 2012


Selina McKee

NICE 'no' for pulmonary fibrosis drug

The National Institute for Health and Clinical Excellence has rejected the use of InterMune's Esbriet (pirfenidone) on the National Health Service to treat patients with idiopathic pulmonary fibrosis.

In draft guidelines published this morning (Thursday), the cost watchdog said that based on current clinical evidence it could not conclude that the drug would be a cost-effective use of NHS resources in this setting.

"Pirfenidone seemed to have a modest but measurable effect on slowing the decline in lung function, but that it was uncertain whether this benefit persisted over time because the clinical trials were short in duration," said Professor Carole Longson, Director of the Centre for Health Technology Evaluation at NICE, explaining the decision.

"Also, it was unclear whether the drug could improve overall survival for people with the disease because of uncertainty about the correct classification of deaths in the clinical trials as being related to idiopathic pulmonary fibrosis or not, a low number of deaths in both treatment and placebo arms and short follow-up," she said.

The Institute has now opened a consultation and said it encourages healthcare professionals, patients with the condition and other relevant parties to comment on the draft recommendations to help shape final guidance.

Idiopathic pulmonary fibrosis - a progressive disease associated with scarring of the lungs - affects around 4000 new adults in the UK every year.  

Esbriet was approved in Europe in March last year.

Click here to order a reprint of this news story.

Tags


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

JobSearch


Head-to-Head Video

 

Website Search


Search News Search Magazine